Anteotech Ltd
ASX:ADO

Watchlist Manager
Anteotech Ltd Logo
Anteotech Ltd
ASX:ADO
Watchlist
Price: 0.02 AUD Market Closed
Market Cap: 54.8m AUD
Have any thoughts about
Anteotech Ltd?
Write Note

Anteotech Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Anteotech Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Anteotech Ltd
ASX:ADO
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Proteomics International Laboratories Ltd
ASX:PIQ
Other Long-Term Assets
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Trajan Group Holdings Ltd
ASX:TRJ
Other Long-Term Assets
AU$4.7m
CAGR 3-Years
5%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Cryosite Ltd
ASX:CTE
Other Long-Term Assets
AU$8.3m
CAGR 3-Years
-13%
CAGR 5-Years
-12%
CAGR 10-Years
30%
Genetic Signatures Ltd
ASX:GSS
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
E
EZZ Life Science Holdings Ltd
ASX:EZZ
Other Long-Term Assets
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Anteotech Ltd
Glance View

Market Cap
54.8m AUD
Industry
Life Sciences Tools & Services

AnteoTech Ltd. is a global nano-technology company, which develops, manufactures, and distributes products for the life sciences, clinical diagnostics and bio-separations markets. The company is headquartered in Eight Mile Plains, Queensland. The company went IPO on 2000-04-11. The firm is focused on the development and commercialization of its intellectual property of specialized surfaces used in the life sciences, diagnostics, energy and medical devices markets. The firm's products include AnteoCoat, AnteoBind and AnteoRelease, which are used in the energy, diagnostic and medical device markets. The firm's AnteoBind is an aqueous nanosized molecular glue (polymeric metal ions) used in a single-step process to facilitate multivalent coordination to bind carbohydrate polymers, antibodies, and proteins to synthetic substrates in assay development. The firm is also developing, SARS-CoV-2 Ag rapid test, which is a single-use, disposable, lateral flow test for the qualitative detection of SARS-CoV-2 nucleocapsid antigen in nasopharyngeal specimens collected from individuals who are suspected of COVID-19 infection.

ADO Intrinsic Value
0.001 AUD
Overvaluation 93%
Intrinsic Value
Price

See Also

Back to Top